Heart failure care has long relied on drugs that ease the heart’s workload, but patients who have just been hospitalized for a worsening episode remain at very high risk. Verquvo (vericiguat) was approved to address that specific window.
By stimulating soluble guanylate cyclase, Verquvo restores nitric oxide signaling to relax blood vessels and improve cardiac function. The once-daily tablet reduces the risk of cardiovascular death and heart failure hospitalization in adults with symptomatic chronic heart failure and reduced ejection fraction following a recent worsening event.
Verquvo remains marketed with no generic competition to date. Its narrow post-hospitalization positioning makes it a useful comparator for heart failure trial design and for tracking how the sGC stimulator class develops in cardiology.
